A top pharma company partnered with Science 37 to conduct the first-ever interventional decentralized clinical trial (DCT) for patients with major depressive disorder (MDD). The trial design included direct-to-patient shipments, in-home mobile nursing visits, artificial intelligence (AI) image capture, and remote clinician-administered rater assessments.
The study aimed to demonstrate the operational feasibility of conducting a double-blind, placebo-controlled efficacy study for a drug administered as an adjunctive treatment to standard-of-care antidepressants in patients with MDD and inadequate response to first-line antidepressants using a fully DCT model.
As stated by the sponsor, “The complex logistics of conducting this first interventional decentralized clinical trial in patients with major depressive disorder were successfully executed.”
Download the poster to review the research findings.
Medical Director, Psychiatry and Behavioral Sciences